Overview

A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and effectiveness of golimumab in patients with active rheumatoid arthritis despite Methotrexate therapy. Another objective is to evaluate the pharmacokinetics of golimumab.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Collaborator:

Mitsubishi Tanabe Pharma Corporation

Treatments:

Antibodies, Monoclonal
Golimumab
Methotrexate